Literature DB >> 31090455

Genetically induced brain inflammation by Cnp deletion transiently benefits from microglia depletion.

Laura Fernandez Garcia-Agudo1, Hana Janova1,2, Lea E Sendler1, Sahab Arinrad1, Agnes A Steixner1, Imam Hassouna1, Evan Balmuth1, Anja Ronnenberg1, Nadine Schopf1, Felicia J van der Flier1, Martin Begemann1,2,3, Henrik Martens4, Martin S Weber5, Susann Boretius2,6, Klaus-Armin Nave2,7, Hannelore Ehrenreich1,2.   

Abstract

Reduced expression of 2'-3'-cyclic nucleotide 3'-phosphodiesterase (Cnp) in humans and mice causes white matter inflammation and catatonic signs. These consequences are experimentally alleviated by microglia ablation via colony-stimulating factor 1 receptor (CSF1R) inhibition using PLX5622. Here we address for the first time preclinical topics crucial for translation, most importantly 1) the comparison of 2 long-term PLX5622 applications (prevention and treatment) vs. 1 treatment alone, 2) the correlation of catatonic signs and executive dysfunction, 3) the phenotype of leftover microglia evading depletion, and 4) the role of intercellular interactions for efficient CSF1R inhibition. Based on our Cnp-/- mouse model and in vitro time-lapse imaging, we report the unexpected discovery that microglia surviving under PLX5622 display a highly inflammatory phenotype including aggressive premortal phagocytosis of oligodendrocyte precursor cells. Interestingly, ablating microglia in vitro requires mixed glial cultures, whereas cultured pure microglia withstand PLX5622 application. Importantly, 2 extended rounds of CSF1R inhibition are not superior to 1 treatment regarding any readout investigated (magnetic resonance imaging and magnetic resonance spectroscopy, behavior, immunohistochemistry). Catatonia-related executive dysfunction and brain atrophy of Cnp-/- mice fail to improve under PLX5622. To conclude, even though microglia depletion is temporarily beneficial and worth pursuing, complementary treatment strategies are needed for full and lasting recovery.-Fernandez Garcia-Agudo, L., Janova, H., Sendler, L. E., Arinrad, S., Steixner, A. A., Hassouna, I., Balmuth, E., Ronnenberg, A., Schopf, N., van der Flier, F. J., Begemann, M., Martens, H., Weber, M. S., Boretius, S., Nave, K.-A., Ehrenreich, H. Genetically induced brain inflammation by Cnp deletion transiently benefits from microglia depletion.

Entities:  

Keywords:  CSF1R inhibitor PLX5622; catatonic signs; executive function; hurdle test; phagocytosis

Mesh:

Substances:

Year:  2019        PMID: 31090455     DOI: 10.1096/fj.201900337R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  6 in total

Review 1.  Colony stimulating factors in the nervous system.

Authors:  Violeta Chitu; Fabrizio Biundo; E Richard Stanley
Journal:  Semin Immunol       Date:  2021-11-04       Impact factor: 11.130

2.  The Anti-Inflammatory Agent Bindarit Attenuates the Impairment of Neural Development through Suppression of Microglial Activation in a Neonatal Hydrocephalus Mouse Model.

Authors:  Eri Iwasawa; Farrah N Brown; Crystal Shula; Fatima Kahn; Sang Hoon Lee; Temugin Berta; David R Ladle; Kenneth Campbell; Francesco T Mangano; June Goto
Journal:  J Neurosci       Date:  2022-01-06       Impact factor: 6.709

3.  The Presentation and Treatment Response of Catatonia in Patients Admitted to the Psychiatric Inpatient Unit at Jimma University Medical Center, Ethiopia.

Authors:  Yimenu Yitayih; Elias Tesfaye; Kristina Adorjan
Journal:  Psychiatry J       Date:  2020-06-30

Review 4.  To Kill a Microglia: A Case for CSF1R Inhibitors.

Authors:  Kim N Green; Joshua D Crapser; Lindsay A Hohsfield
Journal:  Trends Immunol       Date:  2020-08-10       Impact factor: 16.687

5.  Peculiar protrusions along tanycyte processes face diverse neural and nonneural cell types in the hypothalamic parenchyma.

Authors:  Roxane Pasquettaz; Irina Kolotuev; Antoine Rohrbach; Cathy Gouelle; Luc Pellerin; Fanny Langlet
Journal:  J Comp Neurol       Date:  2020-06-24       Impact factor: 3.215

6.  Autoantibodies against NMDA receptor 1 modify rather than cause encephalitis.

Authors:  Justus B H Wilke; Martin Hindermann; Stefan A Berghoff; Svenja Zihsler; Sahab Arinrad; Anja Ronnenberg; Nadine Barnkothe; Agnes A Steixner-Kumar; Stefan Röglin; Winfried Stöcker; Michael Hollmann; Klaus-Armin Nave; Fred Lühder; Hannelore Ehrenreich
Journal:  Mol Psychiatry       Date:  2021-07-30       Impact factor: 15.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.